The authors reply

New England Journal of Medicine

Volumn 377, Issue 25, 2017, Pages 2503-2504

  Wolchok, Jedd D ^a   Rollin, Linda ^b   Larkin, James ^c  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; IPILIMUMAB; NIVOLUMAB;

BRAF GENE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL DECISION MAKING; DRUG SAFETY; DRUG WITHDRAWAL; GENE MUTATION; HUMAN; LETTER; MELANOMA; MONOTHERAPY; PRIORITY JOURNAL; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 85039797210     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1714339     Document Type: Letter

References (2)

1. Schadendorf D, Wolchok JD, Hodi FS, et al. Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with nivolumab and ipilimumab because of adverse events: a pooled analysis of randomized phase II and III trials. J Clin Oncol 2017; 35: 3807-14.
2. Young A, Ngiow SF, Madore J, et al. Targeting adenosine in BRAF-mutant melanoma reduces tumor growth and metastasis. Cancer Res 2017; 77: 4684-96.